COMMUNIQUÉS West-GlobeNewswire

Novo Nordisk A/S: Election of employee representatives to the Board of Directors of Novo Nordisk A/
26/02/2018
Bagsværd, 26 February 2018 - The employees of Novo Nordisk A/S have conducted the election of employee representatives to the Board of Directors of Novo Nordisk A/S. The following members were elected for the next four [...]
Teladoc Earns Surescripts Certification for Medication History Services
26/02/2018
PURCHASE, NY, Feb. 26, 2018 (GLOBE NEWSWIRE) -- HIMSS Booth #3860 - Teladoc , Inc. (NYSE: TDOC ) the world’s largest and most trusted provider of virtual care delivery services, announced today that it has been [...]
Auris Medical to Host Key Opinion Leader Call Focused on Keyzilen® Tinnitus Program on March 5, 2018
26/02/2018
Zug, Switzerland, February 26, 2018 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, today announced [...]
Fortress Biotech Announces Aevitas Therapeutics Enters Sponsored Research Agreement with the University of Massachusetts Medical School to Advance AAV Gene Therapies
26/02/2018
SRA with lab of Guangping Gao, Ph.D., to explore construct optimization in AAV gene therapies for complement-mediated diseases Dr. Gao to serve as first member of Aevitas’ recently launched scientific advisory board NEW [...]
Hemispherx To Supply Ampligen for Pancreatic Cancer Patients in Canada Under Special Access Program
26/02/2018
ORLANDO, Fla., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB) said it is expanding its partnership with myTomorrows to supply Ampligen® for pancreatic cancer patients in Canada under a [...]
Marrone Bio Innovations and Groundwork BioAg Bio-stacked Microbial Seed Treatments Result in Increased Corn and Soybean Yields for the Second Field Trial Season
26/02/2018
DAVIS, Calif. and MOSHAV MAZOR, Israel, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII ) (MBI), a leading provider of bio-based pest management and plant health products for agriculture, [...]
Horizon Blue Cross Blue Shield of New Jersey to Cover Interpace’s Molecular Thyroid Tests
26/02/2018
PARSIPPANY, N.J., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG ) (“Interpace” or “the Company”), a fully integrated commercial and bioinformatics company that provides clinically [...]
Nephros Reports 2017 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
26/02/2018
SOUTH ORANGE, N.J., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid- [...]
Avid Bioservices Announces Resignation of Chief Financial Officer
26/02/2018
TUSTIN, Calif., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO ) (NASDAQ: CDMOP ), a company working to improve patient lives by providing high quality biologics manufacturing services to [...]
Novo Nordisk A/S - Share repurchase programme
26/02/2018
Bagsværd, Denmark, 26 February 2018 - On 5 February 2018, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April [...]
Medtronic Receives FDA Approval for New Arm Indication for Guardian(TM) Sensor 3 - Further Enhancing the MiniMed(TM) 670G Hybrid Closed Loop Experience
26/02/2018
DUBLIN- February 26, 2018 - Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced that the U.S. Food and Drug Administration (FDA) has approved a new arm indication for the Guardian(TM) [...]
Neos Therapeutics Launches Adzenys ER™ (amphetamine) Extended-Release Oral Suspension in U.S. for the Treatment of ADHD in Patients 6 Years and Older
26/02/2018
DALLAS and FORT WORTH, Texas, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS ), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR [...]
Catalyst Biosciences Announces Manufacturing Agreement with AGC Biologics for Subcutaneous Factor IX Product CB 2679d
26/02/2018
Catalyst plans to initiate a Phase 2b study of CB 2679d in Q3 2018 SOUTH SAN FRANCISCO, Calif., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO ), a clinical-stage biopharmaceutical company [...]
Vericel to Present at the 13th Annual Canaccord Genuity Musculoskeletal Conference
26/02/2018
CAMBRIDGE, Mass., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ: VCEL ), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, [...]
K2M and International Spine Study Group Foundation Collaborate to Advance Data Management Using BACS®
26/02/2018
LEESBURG, Va., Feb. 26, 2018 (GLOBE NEWSWIRE) -- K2M Group Holdings, Inc. (NASDAQ: KTWO ) (the "Company" or "K2M"), a global leader of complex spine and minimally invasive solutions focused on achieving three- [...]
Athenex, Inc. to Report Fourth Quarter and Full Year 2017 Earnings Results on March 26, 2018
26/02/2018
BUFFALO, N.Y., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX ), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of [...]
Profound Medical to Participate in 2018 BTIG Healthcare Conference
26/02/2018
TORONTO, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V: PRN ) (OTCQX:PRFMF) (“Profound” or the “Company”), the only company to offer a therapeutic platform that provides the precision of real-time MR [...]
ARCA biopharma Reports Topline Phase 2B Results for GENETIC-AF Clinical Trial
26/02/2018
-------------------------------------------------------------------------------------------------- Gencaro Demonstrates Comparable Efficacy to Active Control and Trend for Potential Gencaro Superiority in US Patient [...]
Endocyte Announces Phase 3 VISION Trial and Provides Update on Corporate Strategy and Reports Fourth Quarter and Year End 2017 Financial Results
26/02/2018
– Phase 3 VISION Trial Design Finalized for 177 Lu-PSMA-617 Following Successful End of Phase 2 Meeting with the FDA – – Announced Agreement for Clinical Supply of No-Carrier-Added Lutetium with ITM – – Added [...]

Pages